Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
featured
  • 560 views
  • 23 Nov, 2020
  • 12 locations
featured
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

idelalisib
lymphoid malignancy
refractory follicular lymphoma
  • 304 views
  • 23 Nov, 2020
  • 6 locations
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …

  • 1 views
  • 29 Jan, 2021
  • 54 locations
  • 0 views
  • 25 Jan, 2021
  • 25 locations
Dose Optimization Study of Idelalisib in Follicular Lymphoma

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other

follicular lymphoma
refractory follicular lymphoma
idelalisib
ct scan
cancer
  • 0 views
  • 02 Apr, 2021
  • 177 locations
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3K inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic

follicular lymphoma
refractory follicular lymphoma
ejection fraction
marginal zone lymphoma
ct scan
  • 127 views
  • 11 Apr, 2021
  • 144 locations
IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3K Inhibitor, in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

  • 0 views
  • 24 Jan, 2021
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

  • 572 views
  • 24 Jan, 2021
  • 3 locations
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Single arm, prospective, multi-centric, phase II study. Patients with histologically confirmed follicular lymphoma, in need of a systemic approach and failing (i.e. with refractory disease [no response or response lasting less than 6 months at any previous line of treatment] or with a proven disease relapse) at least 2 previous …

follicular lymphoma
idelalisib
refractory follicular lymphoma
obinutuzumab
lactate dehydrogenase
  • 0 views
  • 27 Jan, 2021
  • 15 locations
CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years.

  • 0 views
  • 26 Jan, 2021
  • 1 location